Needham Reaffirms Buy Recommendation for Ionis Pharmaceuticals, Sees 7.56% Upside

Needham maintains a "Buy" recommendation for Ionis Pharmaceuticals (IONS) with an average one-year price target of $77.31/share, a 7.56% increase from its latest closing price. The projected annual revenue is $990MM, a 2.46% increase, and the projected non-GAAP EPS is -$2.58. Institutional ownership has increased by 5.17% with 712 funds reporting positions in the company.